OBJECTIVES: With HIV treatment prolonging survival and HIV infection now managed as a chronic illness, quality of life (QOL) is important to evaluate in persons living with HIV (PLWH). We assessed at study entry the QOL of antiretroviral-naïve PLWH with CD4 counts > 500 cells/μL in the Strategic Timing of AntiRetroviral Treatment (START) clinical trial. METHODS:QOL was assessed with: (1) a visual analogue scale (VAS) for self-assessment of overall current health; (2) the Short-Form 12-Item Version 2 Health Survey(®) (SF-12V2), for which responses are summarized into eight individual QOL domains plus component summary scores for physical health [the Physical Health Component Summary (PCS)] and mental health [the Mental Health Component Summary (MCS)]. The VAS and eight domain scores were scaled from 0 to 100. Mean QOL measures were calculated overall and by demographic, clinical and behavioural factors. RESULTS: A total of 4631 participants completed the VAS and 4119 the SF-12. The mean VAS score (with standard deviation) was 80.9 ± 15.7. Mean SF-12 domain scores were lowest for vitality (66.3 ± 26.4) and mental health (68.6 ± 21.4), and highest for physical functioning (89.3 ± 23.0) and bodily pain (88.0 ± 21.4). Using multiple linear regression, PCS scores were lower (P < 0.001) for Asians, North Americans, female participants, older participants, and those with less education, longer duration of known HIV infection, alcoholism/substance dependence and body mass index ≥ 30 kg/m(2) . MCS scores were highest (P < 0.001) for Africans, South Americans and older participants, and lowest for female participants, current smokers and those with alcoholism/substance dependence. CONCLUSIONS: In this primarily healthy population, QOL was mostly favourable, emphasizing that it is important that HIV treatments do not negatively impact QOL. Self-assessed physical health summary scores were higher than mental health scores. Factors such as older age and geographical region had different effects on perceived physical and mental health.
RCT Entities:
OBJECTIVES: With HIV treatment prolonging survival and HIV infection now managed as a chronic illness, quality of life (QOL) is important to evaluate in persons living with HIV (PLWH). We assessed at study entry the QOL of antiretroviral-naïve PLWH with CD4 counts > 500 cells/μL in the Strategic Timing of AntiRetroviral Treatment (START) clinical trial. METHODS: QOL was assessed with: (1) a visual analogue scale (VAS) for self-assessment of overall current health; (2) the Short-Form 12-Item Version 2 Health Survey(®) (SF-12V2), for which responses are summarized into eight individual QOL domains plus component summary scores for physical health [the Physical Health Component Summary (PCS)] and mental health [the Mental Health Component Summary (MCS)]. The VAS and eight domain scores were scaled from 0 to 100. Mean QOL measures were calculated overall and by demographic, clinical and behavioural factors. RESULTS: A total of 4631 participants completed the VAS and 4119 the SF-12. The mean VAS score (with standard deviation) was 80.9 ± 15.7. Mean SF-12 domain scores were lowest for vitality (66.3 ± 26.4) and mental health (68.6 ± 21.4), and highest for physical functioning (89.3 ± 23.0) and bodily pain (88.0 ± 21.4). Using multiple linear regression, PCS scores were lower (P < 0.001) for Asians, North Americans, female participants, older participants, and those with less education, longer duration of known HIV infection, alcoholism/substance dependence and body mass index ≥ 30 kg/m(2) . MCS scores were highest (P < 0.001) for Africans, South Americans and older participants, and lowest for female participants, current smokers and those with alcoholism/substance dependence. CONCLUSIONS: In this primarily healthy population, QOL was mostly favourable, emphasizing that it is important that HIV treatments do not negatively impact QOL. Self-assessed physical health summary scores were higher than mental health scores. Factors such as older age and geographical region had different effects on perceived physical and mental health.
Authors: A G E M de Boer; J J B van Lanschot; P F M Stalmeier; J W van Sandick; J B F Hulscher; J C J M de Haes; M A G Sprangers Journal: Qual Life Res Date: 2004-03 Impact factor: 4.147
Authors: B Gandek; J E Ware; N K Aaronson; G Apolone; J B Bjorner; J E Brazier; M Bullinger; S Kaasa; A Leplege; L Prieto; M Sullivan Journal: J Clin Epidemiol Date: 1998-11 Impact factor: 6.437
Authors: Prabha S Chandra; Charu Gandhi; P Satishchandra; Anupa Kamat; Anita Desai; V Ravi; Raymond L Ownby; D K Subbakrishna; Mahendra Kumar Journal: Qual Life Res Date: 2006-10-11 Impact factor: 4.147
Authors: N Langebeek; H G Sprenger; E H Gisolf; P Reiss; M A G Sprangers; Jc Legrand; C Richter; P T Nieuwkerk Journal: HIV Med Date: 2013-11-11 Impact factor: 3.180
Authors: I Marion de Boer-van der Kolk; Mirjam A G Sprangers; Jan M Prins; Colette Smit; Frank de Wolf; Pythia T Nieuwkerk Journal: Clin Infect Dis Date: 2010-01-15 Impact factor: 9.079
Authors: Isabel Cuéllar-Flores; Talía Saínz; Carlos Velo; María Isabel González-Tomé; Cristina García-Navarro; Carolina Fernández-Mcphee; Sara Guillén; José Tomás Ramos; Pilar Miralles; Rafael Rubio; José Ignacio Bernardino; Luis Prieto; Pablo Rojo; Santiago Jiménez de Ory; Maria Luisa Navarro Journal: World J Pediatr Date: 2019-07-08 Impact factor: 2.764
Authors: Alan R Lifson; Birgit Grund; Edward M Gardner; Richard Kaplan; Eileen Denning; Nicole Engen; Catherine L Carey; Fabian Chen; Sounkalo Dao; Eric Florence; Jesus Sanz; Sean Emery Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: J A McGowan; L Sherr; A J Rodger; M Fisher; A Miners; J Anderson; M A Johnson; J Elford; S Collins; G Hart; A N Phillips; A Speakman; F C Lampe Journal: HIV Med Date: 2016-07-07 Impact factor: 3.180
Authors: Leonard Emuren; Seth Welles; Alison A Evans; Marcia Polansky; Jason F Okulicz; Grace Macalino; Brian K Agan Journal: PLoS One Date: 2017-06-07 Impact factor: 3.240